Physician profile
Lisa Lanning
NPI 1023207784
$1,466.92
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $255 · 2021: $416 · 2022: $160 · 2023: $30.47 · 2024: $14.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $392.02 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $259.33 | 2019-2022 | |
| Glaxosmithkline, LLC. | $113.47 | 2019-2021 | |
| Abbvie INC. | $97.08 | 2019-2022 | |
| Amgen INC. | $80.40 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $70.44 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $69.05 | 2021-2023 | |
| Gilead Sciences, INC. | $57.13 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $57.10 | 2019-2021 | |
| Pfizer INC. | $42.65 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.00 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $30.92 | 2019 | |
| Merck Sharp & Dohme LLC | $24.35 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.33 | 2022 | |
| Amarin Pharma, INC. | $20.64 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.18 | 2020 | |
| Cvrx, INC. | $14.06 | 2024 | Barostim Neo System |
| Eisai INC. | $13.58 | 2021 | |
| Horizon Therapeutics Plc | $12.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.93 | 2019 | |
| Hikma Pharmaceuticals USA | $11.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Lanning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.